{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T16:23:47Z","timestamp":1762100627409},"reference-count":58,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.2217\/14796694.3.1.29","type":"journal-article","created":{"date-parts":[[2007,2,5]],"date-time":"2007-02-05T15:58:32Z","timestamp":1170691112000},"page":"29-42","source":"Crossref","is-referenced-by-count":4,"title":["Alemtuzumab in Chronic Lymphocytic Leukemia"],"prefix":"10.1080","volume":"3","author":[{"given":"Danelle F","family":"James","sequence":"first","affiliation":[{"name":"University of California, San Diego, Division of Hematology & Oncology, UCSD Moores Cancer Center, Room #4311, 3855 Health Sciences Drive, La Jolla, CA92093-0820USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J","family":"Kipps","sequence":"additional","affiliation":[{"name":"University of California, San Diego, Division of Hematology & Oncology, UCSD Moores Cancer Center, Room #4305, 3855 Health Sciences Drive, La Jolla, CA92093-0820, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2007,2,5]]},"reference":[{"key":"e_1_3_1_3_1","first-page":"243","volume-title":"Methods in Molecular Medicine.","author":"Waldmann GHAH","year":"2000","unstructured":"Waldmann GHAH : From laboratory to clinic: the story of CAMPATH-1. Diagnostic and therapeutic antibodies. In:Methods in Molecular Medicine. Urch AGAC (Ed.). Humana Press, Totowa, NJ, USA 40, 243\u2013266 (2000)."},{"key":"e_1_3_1_4_1","doi-asserted-by":"publisher","DOI":"10.1080\/146532401753174098"},{"key":"e_1_3_1_5_1","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.2005.1702"},{"key":"e_1_3_1_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.47.4.313"},{"key":"e_1_3_1_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.3.807.807"},{"key":"e_1_3_1_8_1","first-page":"1522","article-title":"Effects of CAMPATH-1 antibodies on the functional activity of monocytes and polymorphonuclear neutrophils.","volume":"21","author":"Fabian I","year":"1993","unstructured":"Fabian I , FlidelO, GadishM, KletterY, SlavinS, NaglerA: Effects of CAMPATH-1 antibodies on the functional activity of monocytes and polymorphonuclear neutrophils.Exp. Hematol.21, 1522\u20131527 (1993).","journal-title":"Exp. Hematol."},{"key":"e_1_3_1_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.12.4684.bloodjournal88124684"},{"key":"e_1_3_1_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20477"},{"key":"e_1_3_1_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V73.6.1431.1431"},{"key":"e_1_3_1_12_1","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.1999.2750"},{"key":"e_1_3_1_13_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.26.11980"},{"key":"e_1_3_1_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/332323a0"},{"key":"e_1_3_1_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)93024-U"},{"key":"e_1_3_1_16_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2061.x"},{"key":"e_1_3_1_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.7.2667"},{"key":"e_1_3_1_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.10.3554"},{"key":"e_1_3_1_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0593"},{"key":"e_1_3_1_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/146532401317070899"},{"key":"e_1_3_1_21_1","first-page":"52","article-title":"The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies.","volume":"26","author":"Dyer MJ","year":"1999","unstructured":"Dyer MJ : The role of CAMPATH-1 antibodies in the treatment of lymphoid malignancies.Semin. Oncol.26, 52\u201357 (1999).","journal-title":"Semin. Oncol."},{"key":"e_1_3_1_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.6037"},{"key":"e_1_3_1_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.4.1567"},{"key":"e_1_3_1_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.06.119"},{"key":"e_1_3_1_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"e_1_3_1_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000006547"},{"key":"e_1_3_1_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.thj.6200325"},{"key":"e_1_3_1_28_1","doi-asserted-by":"crossref","unstructured":"Stilgenbauer S Kr\u00f6berA BuschR EichhorstBet al.: 17p deletion predicts for inferior overall survival after fludarabine \u2013 based first line therapy in chronic lymphocytic leukemia: first analysis of genetics in the CLL4 trial of the GCLLSG. American Society of Hematology Annual Meeting Abstracts. Atlanta GA USA 106 Abstract 715 (2005).","DOI":"10.1182\/blood.V106.11.715.715"},{"key":"e_1_3_1_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-10-3729"},{"key":"e_1_3_1_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.13.13"},{"key":"e_1_3_1_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.2510.2510"},{"key":"e_1_3_1_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200208083470619"},{"key":"e_1_3_1_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.478.478"},{"key":"e_1_3_1_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.6.2245"},{"key":"e_1_3_1_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.9950"},{"key":"e_1_3_1_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.1.29"},{"key":"e_1_3_1_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.021"},{"key":"e_1_3_1_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.12.051"},{"key":"e_1_3_1_39_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03959.x"},{"key":"e_1_3_1_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-1952"},{"key":"e_1_3_1_41_1","first-page":"1207","volume-title":"Leukemia","author":"Lin TS","year":"2005","unstructured":"Lin TS , FlinnIW, LucasMSet al.: Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. Leukemia19, 1207\u20131210 (2005)."},{"key":"e_1_3_1_42_1","article-title":"Varying modes of maintenance therapy with Campath-1H in chronic lymphocytic leukemia (CLL). American Society of Clinical Oncology.Orlando, FL, USA;","author":"Kanti RR","year":"2002","unstructured":"Kanti RR , NancyDJ, CrowleyA, AhmedS: Varying modes of maintenance therapy with Campath-1H in chronic lymphocytic leukemia (CLL). American Society of Clinical Oncology.Orlando, FL, USA;Proc. Am. Soc. Clin. Oncol. (2002).","journal-title":"Proc. Am. Soc. Clin. Oncol."},{"key":"e_1_3_1_43_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190310001615675"},{"issue":"11","key":"e_1_3_1_44_1","article-title":"(2506) subcutaneous alemtuzumab following fludarbine for previously untreated patients with chronic lymphocytic leukemia (CLL): CALGB Study 19901. American Society of Hematology Annual Meeting Abstracts. San Diego, CA, USA;","volume":"102","author":"Kanti RR","year":"2003","unstructured":"Kanti RR , ByrdJC, PetersonB, GautierM, LarsonRA: (2506) subcutaneous alemtuzumab following fludarbine for previously untreated patients with chronic lymphocytic leukemia (CLL): CALGB Study 19901. American Society of Hematology Annual Meeting Abstracts. San Diego, CA, USA;Blood102(11) Abstract 2506 (2003).","journal-title":"Blood"},{"key":"e_1_3_1_45_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11871"},{"issue":"11","key":"e_1_3_1_46_1","article-title":"Alemtuzumab for minimal residual disease in CLL. American Society of Hematology Annual Meeting Abstracts.","volume":"102","author":"O\u2018Brien SM","year":"2003","unstructured":"O\u2018Brien SM , GribbenJG, ThomasDA, AlbitarMet al.: Alemtuzumab for minimal residual disease in CLL. American Society of Hematology Annual Meeting Abstracts. San Diego, CA, USA; Blood102(11) Abstract 371 (2003).","journal-title":"Blood"},{"key":"e_1_3_1_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403354"},{"key":"e_1_3_1_48_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1996.450989.x"},{"key":"e_1_3_1_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V108.11.301.301"},{"key":"e_1_3_1_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.2505.2505"},{"key":"e_1_3_1_51_1","first-page":"220","volume-title":"Clin. Lymphoma","author":"Keating M","year":"2004","unstructured":"Keating M , CoutreS, RaiKet al.: Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia. Clin. Lymphoma4, 220\u20137 (2004)."},{"key":"e_1_3_1_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05789.x"},{"key":"e_1_3_1_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403258"},{"key":"e_1_3_1_54_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01676.x"},{"key":"e_1_3_1_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403984"},{"key":"e_1_3_1_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-10-3270"},{"key":"e_1_3_1_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11551"},{"key":"e_1_3_1_58_1","article-title":"Patients with refractory B-CLL and T-PLL treated with alemtuzumab on a compassionate basis. Report of efficacy and safety of CAM 511 trial","author":"Rai KR","year":"2002","unstructured":"Rai KR , MJK, CoutreS: Patients with refractory B-CLL and T-PLL treated with alemtuzumab on a compassionate basis. Report of efficacy and safety of CAM 511 trial. American Society of Hematology Annual Meeting Abstracts. Philadelphia, PA, USA (2002).","journal-title":"American Society of Hematology Annual Meeting Abstracts."},{"key":"e_1_3_1_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V104.11.340.340"},{"key":"e_1_3_1_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0159"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/14796694.3.1.29","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T06:44:39Z","timestamp":1719125079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/14796694.3.1.29"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["10.2217\/14796694.3.1.29"],"URL":"https:\/\/doi.org\/10.2217\/14796694.3.1.29","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}